Authors and Disclosures
Author(s)
Mark J. Alberts, MD
Mark J. Alberts, MD, Professor of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois; Director, Stroke Program, Northwestern Memorial Hospital, Chicago, Illinois
Mark J. Alberts, MD, has disclosed that he has served as a consultant to, received research grants or honoraria from, or served on the speaker's bureau, advisory board, or review panel of AGA Medical, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb Company, diaDexus, Inc., Eli Lilly and Company, Genentech, Inc., Kos Pharmaceuticals, Inc., Medscape, Merck & Co., Inc., Novo Nordisk, PDL BioPharma, Inc., Pfizer Inc., PhotoThera, Inc., sanofi-aventis, Schering-Plough Corporation, TAP Pharmaceutical Products, Inc, and The Medicines Company. Dr. Alberts has also disclosed that he has received royalties from Duke University/Athena Diagnostics for an ApOE Genotype Test.
After PCI, 1-Month Beats 12-Month DAPT inHigh-Risk Patients
The Role of Aspirin Today
COMMENTARY
Clopidogrel Plus Aspirin Reduce Stroke Risk in Certain Patients With Atrial Fibrillation
Mark J. Alberts, MD
DisclosuresApril 23, 2009
Discuss Clopidogrel Plus Aspirin Reduce Stroke Risk in Certain Patients With Atrial Fibrillation
Citation: Connolly SJ, Pogue J, Hart RG, et al; The ACTIVE Investigators. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med. 2009 Apr 3. [Epub ahead of print]
Medscape Neurology © 2009 Medscape, LLC
Cite this: Mark J. Alberts. Clopidogrel Plus Aspirin Reduce Stroke Risk in Certain Patients With Atrial Fibrillation - Medscape - Apr 23, 2009.
Tables
Authors and Disclosures
Authors and Disclosures
Author(s)
Mark J. Alberts, MD
Mark J. Alberts, MD, Professor of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois; Director, Stroke Program, Northwestern Memorial Hospital, Chicago, Illinois
Mark J. Alberts, MD, has disclosed that he has served as a consultant to, received research grants or honoraria from, or served on the speaker's bureau, advisory board, or review panel of AGA Medical, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb Company, diaDexus, Inc., Eli Lilly and Company, Genentech, Inc., Kos Pharmaceuticals, Inc., Medscape, Merck & Co., Inc., Novo Nordisk, PDL BioPharma, Inc., Pfizer Inc., PhotoThera, Inc., sanofi-aventis, Schering-Plough Corporation, TAP Pharmaceutical Products, Inc, and The Medicines Company. Dr. Alberts has also disclosed that he has received royalties from Duke University/Athena Diagnostics for an ApOE Genotype Test.